NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
Travera Inc
Ellipses Pharma
AbbVie
GlaxoSmithKline
Imunon
Teva Branded Pharmaceutical Products R&D, Inc.
CytRx